Developing a cancer therapy, diagnostic or medical device can require years of expensive research before private investors are prepared to take the risk.

The National Cancer Institute SBIR/STTR programme helps U.S. small businesses fund that early and translational development without requiring founders to surrender equity or intellectual-property ownership.

NCI supports investigator-initiated SBIR and STTR grants across cancer technology and accepts parent-grant submissions three times each year.

The September 2026 cycle has passed. Under the current parent announcements, the remaining standard deadlines are January 5 and April 5, 2027.

What Does NCI Fund?

NCI is looking for technologies capable of reducing or eliminating the burden of cancer.

Current areas of interest include:

• Novel cancer therapeutics;
• Radiation and treatment devices;
• In vitro and in vivo diagnostics;
• Cancer imaging;
• Cancer research tools;
• Cancer prevention technologies;
• Digital health;
• Precision-medicine technologies.

NCI gives particular attention to products addressing significant unmet medical needs and technologies with a credible commercialisation pathway.

How Much Funding Can NCI Provide?

Under the current parent announcements, NCI generally allows budgets of up to:

Phase I: $700,000.

Phase II: $2.5 million.

These are total project costs, and applicants should still request only the amount reasonably required.

NCI also participates in later-stage programmes.

Under the Parent Phase IIB Strategic Breakthrough Award, NCI’s listed limit is as high as $15 million, although the current NCI priority for that mechanism focuses on late-stage clinical trials for drugs and devices addressing rare and pediatric cancers.

NCI also participates in the Commercialization Readiness Pilot, which can support qualifying recent Phase II or Phase IIB projects.

SBIR or STTR?

Use SBIR when the small business will lead and perform most of the research.

Use STTR when commercialisation depends on a formal partnership with a nonprofit research institution.

Both awards go to the small business.

For STTR, at least 40% of the project must be performed by the company and at least 30% by the research institution.

What Does a Competitive NCI Application Look Like?

Scientific innovation matters, but NCI is not funding basic research simply because it involves cancer.

The application should lead towards a product.

For a diagnostic, explain who will order it, how it compares with the current standard of care and what evidence will be needed for regulatory approval and reimbursement.

For a therapeutic, address the target, mechanism, development pathway, manufacturing and future clinical strategy.

For digital health, demonstrate that the technology offers measurable advantages rather than simply digitising an existing service.

Commercialisation planning becomes increasingly important as the project advances.

NCI Support Goes Beyond the Grant

NCI operates a dedicated SBIR Development Center rather than treating small-business awards solely as another grant mechanism.

The institute also provides programmes covering entrepreneurial training, regulatory interaction, investor preparation and commercialisation support.

NCI has described its role as similar to an early-stage investor, but without taking an equity or intellectual-property position in funded companies.

That combination can be particularly attractive for biotechnology companies that need to generate expensive technical evidence before private investment becomes realistic.

Who Can Apply?

The recipient must be an eligible U.S. small business concern.

Foreign companies cannot directly receive NCI SBIR/STTR awards.

The business should therefore verify federal ownership, employee-count and registration rules well before preparing the scientific proposal.

Application Deadlines

The next standard parent deadline is January 5, 2027, followed by April 5, 2027.

NCI recommends engaging programme staff before submission, especially where applicants are uncertain about institute fit, clinical-trial requirements or the appropriate funding phase.

Explore official NCI SBIR/STTR small business funding

For oncology entrepreneurs, NCI funding can do something private capital frequently struggles to do: finance high-risk scientific development before the commercial risk has been fully removed.